Inflammatory Breast Carcinoma
Associated Genetic Biomarkers
NCI Definition: An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma. 
Inflammatory breast carcinomas most frequently harbor alterations in TP53, NOTCH2, MYC, MDM4, and MCL1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in inflammatory breast carcinoma .
There are 4 clinical trials for inflammatory breast carcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain inflammatory breast carcinoma as an inclusion criterion, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open).
ERBB2 is the most frequent gene inclusion criterion for inflammatory breast carcinoma clinical trials .
Cyclophosphamide, pertuzumab, and trastuzumab are the most common interventions in inflammatory breast carcinoma clinical trials.
Significant Genes in Inflammatory Breast Carcinoma
ERBB2 is mutated in 8.33% of inflammatory breast carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 4 clinical trials for inflammatory breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and inflammatory breast carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) .
Cyclophosphamide, pertuzumab, and trastuzumab are the most frequent therapies in inflammatory breast carcinoma trials with ERBB2 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.